Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity

This publication has 30 references indexed in Scilit:

• European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma
  Journal of Clinical Oncology, 2000
• Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)
  Blood, 1999
• Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab
  Journal of Clinical Oncology, 1999
• Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
  New England Journal of Medicine, 1999
• Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study
  British Journal of Haematology, 1999
• A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate
  New England Journal of Medicine, 1999
• Human cytokines suppress apoptosis of leukaemic CD5⁺ B cells and preserve expression of bcl‐2
  Immunology & Cell Biology, 1997
• Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs
  Cancer Biotherapy & Radiopharmaceuticals, 1997
• Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro
  British Journal of Haematology, 1996
• Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia.
  The Journal of Experimental Medicine, 1993